Exactech Inc (EXAC) 22.33 $EXAC
Exactech reports February 17
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 8:56AM CST
EXAC: 22.33 (-0.28)
Exactech Schedules Fourth Quarter and Year End 2014 Earnings Release and Conference Call
Business Wire - Tue Feb 03, 8:40AM CST
Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, will release its fourth quarter and year end 2014 financial results after the market closes on Tuesday, February 17th, 2015. A copy of the earnings release will be available at http://www.hawkassociates.com.
EXAC: 22.33 (-0.28)
Global Organ and Tissue Transplantation Market
PR Newswire - Thu Jan 29, 7:27AM CST
This report analyzes the worldwide markets for Organ and Tissue Transplantation in Number of Procedures. The global and regional markets (except the US) for 'Organ and Tissue Transplantation' in this report are analyzed by the following Product Segments - Organ Tranplantation (Heart, Kidneys, Liver, Pancreas, and Lungs). The US market for 'Organ and Tissue Transplantation' in this report is analyzed by the following Product Segments: Organ Type (Heart, Kidneys, Liver, Pancreas, Lungs, and Intestine), Tissue Type (Cornea, Heart Valve, Skin Grafts, Vascular Grafts, Bone Marrow, and Bone Grafts), and Bone Graft Transplantation (By Graft Type: Autologous Graft, Allograft, and Other Materials; By Application Type: General Orthopedics, Spinal Fusions, and Cranio/Maxillofacial). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 24 companies including many key and niche players such as -
EXAC: 22.33 (-0.28), CRY: 11.30 (-0.10)
Exactech Acquires Surgical Technology Partner BlueOrtho - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 21, 12:30PM CST
Producer of bone and joint restoration products, Exactech Inc. (EXAC) recently announced that it has acquired BlueOrtho SAS ??? a firm engaged in computer-assisted surgical technology development and manufacturing.
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), EXAC: 22.33 (-0.28), SURG: 4.44 (-0.02)
Exactech Acquires Industry-Leading Computer-Assisted Surgical Technology Company
Business Wire - Tue Jan 20, 7:12AM CST
Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder and spine, announced today the acquisition of an industry-leading computer-assisted surgical technology development and manufacturing firm, Grenoble France-based BlueOrtho SAS.
EXAC: 22.33 (-0.28)
Global Spinal Fixation Industry Report 2015
M2 - Mon Jan 12, 6:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/vnqxn5/global_spinal) has announced the addition of the "Global Spinal Fixation Industry Report 2015" report to their offering. The Spinal Fixation Industry industry Report is a professional and in-depth study on the current state of the Spinal Fixation Industry Industry with a focus on the Chinese situation. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Spinal Fixation Industry market analysis is provided for both the international and Chinese domestic situations including development trends, competitive landscape analysis, key regions development status and a comparison analysis between the international and Chinese markets. Development policies and plans are also discussed and manufacturing processes and cost structures analyzed. Spinal Fixation Industry industry import/export consumption, supply and demand figures and cost price and production value gross margins are also provided. The report focuses on the Spinal Fixation Industry industry players providing information such as company profiles, product picture and specification, capacity production, price, cost, production value and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The Spinal Fixation Industry industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered. Key Topics Covered: - Spinal Fixation Industry Overview - Spinal Fixation International and China Market Analysis - Spinal Fixation Technical Data and Manufacturing Plants Analysis - Spinal Fixation Production by Regions by Technology by Applications - Spinal Fixation Manufacturing Process and Cost Structure - 2009-2014 Spinal Fixation Productions Supply Sales Demand Market Status and Forecast - Spinal Fixation Key Manufacturers Analysis - Up and Down Stream Industry Analysis - Spinal Fixation Marketing Channels Analysis - 2015-2020 Spinal Fixation Productions Supply Sales Demand Market Status and Forecast - Spinal Fixation Industry Development Proposals - Spinal Fixation New Project Investment Feasibility Analysis - Global and China Spinal Fixation Industry Research Conclusions Companies Mentioned - A-Spine - Aesculap - Alphatec Spine Inc. - BK Meditech - Bestbio-Technical - Bonovo - ChunLi - DePuy Spine Inc. (J&J) - Dingjian Medical Instrument - Exactech Inc. - Fule Science & Technology - IRENE(Nation Medical Group) - Jiangsu IDEAL Medical Science & Technology - Kanghui Medical (Medtronic Sofamor Danek USA) - LDR Medical - Medtronic - NuVasive Inc. - PASSmed - PW MedTech - Sintea Plustek - Stryker Spine - Trauson Holding (Stryker) - WEGO - Waston - Xingang Medical Instrument - Xinrong Best Medical Instrument - Zimmer Holdings For more information visit http://www.researchandmarkets.com/research/vn...bal_spinal
ZMH: 119.33 (+1.18), MDT: 75.26 (+0.33), EXAC: 22.33 (-0.28), NUVA: 46.99 (+0.30)
Exactech's Equinoxe Shoulder System: 10 Years of Success - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 4:55PM CST
Developer of orthopedic implant devices Exactech Inc. (EXAC) recently announced the 10th year anniversary of its Equinoxe Shoulder System, a product line in its shoulder business.
ZMH: 119.33 (+1.18), GMED: 24.85 (+0.45), EXAC: 22.33 (-0.28), SYK: 94.51 (+1.14)
Industry's Fastest Growing Shoulder System Marks 10 Years of Improving Patient Outcomes
Business Wire - Mon Nov 17, 7:08AM CST
Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, this week recognizes the 10th anniversary of its unique Equinoxe(R) Shoulder System.
EXAC: 22.33 (-0.28)
Exactech's (EXAC) Octane Elevate to Advance Spine Surgery - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 5:15PM CST
Developer of orthopedic implant devices, Exactech Inc. (EXAC), recently announced the launch of Octane Elevate, a self-distracting lumber fusion device made of Poly Ether Ether Ketone (PEEK), a colorless organic thermoplastic polymer.
ZMH: 119.33 (+1.18), GMED: 24.85 (+0.45), EXAC: 22.33 (-0.28), SYK: 94.51 (+1.14)
Globus Medical to Redefine Spinal Fusion with ALTERA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 5:07PM CST
Manufacturer of musculoskeletal implants, Globus Medical Inc. (GMED), recently announced the launch of ALTERA, which is claimed to be the first minimally intrusive expandable spacer.
ZMH: 119.33 (+1.18), GMED: 24.85 (+0.45), EXAC: 22.33 (-0.28), SYK: 94.51 (+1.14)
Exactech (EXAC) Down to Strong Sell On Dismal Q3 Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 12:30PM CST
Exactech Inc.'s (EXAC) lackluster third-quarter 2014 results (reported on Oct 21), with both earnings and revenues missing expectations, have set a negative earnings estimate revision trend for the company.
ICUI: 88.98 (+0.42), BABY: 36.96 (-0.03), EXAC: 22.33 (-0.28), IDXX: 159.08 (+1.72)
Exactech Offers High Growth And Trades At A Discount To Fair Value
Jonathan Weber - at Seeking Alpha - Wed Nov 12, 12:16PM CST
EXAC: 22.33 (-0.28)
Exactech Launches Octane(R) Elevate Peek Spacer System For Lumbar Interbody Fusion Procedures
Business Wire - Tue Nov 11, 6:56AM CST
Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announces that its spine division has launched Octane(R) Elevate, a Poly Ether Ether Ketone (PEEK) spacer system, at the North American Spine Society Annual Meeting (NASS).
EXAC: 22.33 (-0.28)
Exactech Shares Down 10.1% Since SmarTrend's Sell Call (EXAC)
Comtex SmarTrend(R) - Thu Oct 30, 11:08AM CDT
SmarTrend identified a Downtrend for Exactech (NASDAQ:EXAC) on July 17th, 2014 at $23.77. In approximately 4 months, Exactech has returned 10.14% as of today's recent price of $21.36.
EXAC: 22.33 (-0.28)
Organ and Tissue Transplantation Markets - Global Strategic Business Report 2014-2020
M2 - Thu Oct 30, 5:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zx4hg8/organ_and_tissue) has announced the addition of the "Organ and Tissue Transplantation - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. This report analyzes the worldwide markets for Organ and Tissue Transplantation in Number of Procedures. The global and regional markets (except the US) for 'Organ and Tissue Transplantation' in this report are analyzed by the following Product Segments Organ Tranplantation (Heart, Kidneys, Liver, Pancreas, and Lungs) The US market for 'Organ and Tissue Transplantation' in this report is analyzed by the following Product Segments: - Organ Type (Heart, Kidneys, Liver, Pancreas, Lungs, and Intestine) - Tissue Type (Cornea, Heart Valve, Skin Grafts, Vascular Grafts, Bone Marrow, and Bone Grafts), - Bone Graft Transplantation (By Graft Type: Autologous Graft, Allograft, and Other Materials; By Application Type: General Orthopedics, Spinal Fusions, and Cranio/Maxillofacial). The report profiles 24 companies including many key and niche players such as: - CryoLife, Inc - Exactech, Inc - Folio Biosciences - K?hler Chemie - LifeCell Corporation - Medtronic, Inc. - Organogenesis, Inc. - Organ Recovery Systems - Organ Transport Systems - XVIVO Perfusion AB Key Topics Covered: I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW 2. MARKET TRENDS 3. TECHNOLOGICAL INNOVATIONS 4. MAJOR ISSUES IMPACTING TRANSPLANTATION MARKET 5. PRODUCT OVERVIEW 6. ARTIFICIAL ORGANS - AN ALTERNATIVE TO SOLID ORGAN TRANSPLANTS 7. PRESERVATION SOLUTIONS & IMMUNOSUPPRESSANT DRUGS 8. REGULATORY ENVIRONMENT 9. PRODUCT DEVELOPMENT/INNOVATIONS 10. RECENT INDUSTRY ACTIVITY 11. FOCUS ON SELECT GLOBAL PLAYERS 12. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. EUROPE 4. ASIA-PACIFIC 5. LATIN AMERICA 6. REST OF WORLD IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 24 - The United States (21) - Europe (2) - - Germany (1) - - Rest of Europe (1) - Middle East (1) For more information visit http://www.researchandmarkets.com/research/zx...and_tissue
MDT: 75.26 (+0.33), EXAC: 22.33 (-0.28), CRY: 11.30 (-0.10)
Exactech's (EXAC) CEO David Petty on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Oct 22, 2:57PM CDT
EXAC: 22.33 (-0.28)
Exactech posts 3Q profit
Automated Insights - Tue Oct 21, 3:28PM CDT
GAINSVILLE, Fla. (AP) _ Exactech Inc. (EXAC) on Tuesday reported net income of $3 million, or 21 cents per share, in its third quarter.
EXAC: 22.33 (-0.28)
Exactech Q3 Revenue Up 4% to $57.9 Million; Net Income Down 6% to $3.0 Million Due to Currency Losses; Q3 Diluted EPS $0.21 vs. $0.23
Business Wire - Tue Oct 21, 3:00PM CDT
Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder and spine, announced today revenue of $57.9 million for the third quarter of 2014, a 4% increase over $55.7 million in the third quarter of 2013. Net income was $3.0 million, or $0.21 per diluted share, compared to $3.2 million, or $0.23 per diluted share, in the same quarter a year ago.
EXAC: 22.33 (-0.28)
Exactech reports February 17
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 8:56AM CST
EXAC: 22.33 (-0.28)
Exactech Schedules Fourth Quarter and Year End 2014 Earnings Release and Conference Call
Business Wire - Tue Feb 03, 8:40AM CST
Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, will release its fourth quarter and year end 2014 financial results after the market closes on Tuesday, February 17th, 2015. A copy of the earnings release will be available at http://www.hawkassociates.com.
EXAC: 22.33 (-0.28)
Global Organ and Tissue Transplantation Market
PR Newswire - Thu Jan 29, 7:27AM CST
This report analyzes the worldwide markets for Organ and Tissue Transplantation in Number of Procedures. The global and regional markets (except the US) for 'Organ and Tissue Transplantation' in this report are analyzed by the following Product Segments - Organ Tranplantation (Heart, Kidneys, Liver, Pancreas, and Lungs). The US market for 'Organ and Tissue Transplantation' in this report is analyzed by the following Product Segments: Organ Type (Heart, Kidneys, Liver, Pancreas, Lungs, and Intestine), Tissue Type (Cornea, Heart Valve, Skin Grafts, Vascular Grafts, Bone Marrow, and Bone Grafts), and Bone Graft Transplantation (By Graft Type: Autologous Graft, Allograft, and Other Materials; By Application Type: General Orthopedics, Spinal Fusions, and Cranio/Maxillofacial). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 24 companies including many key and niche players such as -
EXAC: 22.33 (-0.28), CRY: 11.30 (-0.10)
Exactech Acquires Surgical Technology Partner BlueOrtho - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 21, 12:30PM CST
Producer of bone and joint restoration products, Exactech Inc. (EXAC) recently announced that it has acquired BlueOrtho SAS ??? a firm engaged in computer-assisted surgical technology development and manufacturing.
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), EXAC: 22.33 (-0.28), SURG: 4.44 (-0.02)
Exactech Acquires Industry-Leading Computer-Assisted Surgical Technology Company
Business Wire - Tue Jan 20, 7:12AM CST
Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder and spine, announced today the acquisition of an industry-leading computer-assisted surgical technology development and manufacturing firm, Grenoble France-based BlueOrtho SAS.
EXAC: 22.33 (-0.28)
Global Spinal Fixation Industry Report 2015
M2 - Mon Jan 12, 6:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/vnqxn5/global_spinal) has announced the addition of the "Global Spinal Fixation Industry Report 2015" report to their offering. The Spinal Fixation Industry industry Report is a professional and in-depth study on the current state of the Spinal Fixation Industry Industry with a focus on the Chinese situation. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Spinal Fixation Industry market analysis is provided for both the international and Chinese domestic situations including development trends, competitive landscape analysis, key regions development status and a comparison analysis between the international and Chinese markets. Development policies and plans are also discussed and manufacturing processes and cost structures analyzed. Spinal Fixation Industry industry import/export consumption, supply and demand figures and cost price and production value gross margins are also provided. The report focuses on the Spinal Fixation Industry industry players providing information such as company profiles, product picture and specification, capacity production, price, cost, production value and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The Spinal Fixation Industry industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered. Key Topics Covered: - Spinal Fixation Industry Overview - Spinal Fixation International and China Market Analysis - Spinal Fixation Technical Data and Manufacturing Plants Analysis - Spinal Fixation Production by Regions by Technology by Applications - Spinal Fixation Manufacturing Process and Cost Structure - 2009-2014 Spinal Fixation Productions Supply Sales Demand Market Status and Forecast - Spinal Fixation Key Manufacturers Analysis - Up and Down Stream Industry Analysis - Spinal Fixation Marketing Channels Analysis - 2015-2020 Spinal Fixation Productions Supply Sales Demand Market Status and Forecast - Spinal Fixation Industry Development Proposals - Spinal Fixation New Project Investment Feasibility Analysis - Global and China Spinal Fixation Industry Research Conclusions Companies Mentioned - A-Spine - Aesculap - Alphatec Spine Inc. - BK Meditech - Bestbio-Technical - Bonovo - ChunLi - DePuy Spine Inc. (J&J) - Dingjian Medical Instrument - Exactech Inc. - Fule Science & Technology - IRENE(Nation Medical Group) - Jiangsu IDEAL Medical Science & Technology - Kanghui Medical (Medtronic Sofamor Danek USA) - LDR Medical - Medtronic - NuVasive Inc. - PASSmed - PW MedTech - Sintea Plustek - Stryker Spine - Trauson Holding (Stryker) - WEGO - Waston - Xingang Medical Instrument - Xinrong Best Medical Instrument - Zimmer Holdings For more information visit http://www.researchandmarkets.com/research/vn...bal_spinal
ZMH: 119.33 (+1.18), MDT: 75.26 (+0.33), EXAC: 22.33 (-0.28), NUVA: 46.99 (+0.30)
Exactech's Equinoxe Shoulder System: 10 Years of Success - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 4:55PM CST
Developer of orthopedic implant devices Exactech Inc. (EXAC) recently announced the 10th year anniversary of its Equinoxe Shoulder System, a product line in its shoulder business.
ZMH: 119.33 (+1.18), GMED: 24.85 (+0.45), EXAC: 22.33 (-0.28), SYK: 94.51 (+1.14)
Industry's Fastest Growing Shoulder System Marks 10 Years of Improving Patient Outcomes
Business Wire - Mon Nov 17, 7:08AM CST
Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, this week recognizes the 10th anniversary of its unique Equinoxe(R) Shoulder System.
EXAC: 22.33 (-0.28)
Exactech's (EXAC) Octane Elevate to Advance Spine Surgery - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 5:15PM CST
Developer of orthopedic implant devices, Exactech Inc. (EXAC), recently announced the launch of Octane Elevate, a self-distracting lumber fusion device made of Poly Ether Ether Ketone (PEEK), a colorless organic thermoplastic polymer.
ZMH: 119.33 (+1.18), GMED: 24.85 (+0.45), EXAC: 22.33 (-0.28), SYK: 94.51 (+1.14)
Globus Medical to Redefine Spinal Fusion with ALTERA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 5:07PM CST
Manufacturer of musculoskeletal implants, Globus Medical Inc. (GMED), recently announced the launch of ALTERA, which is claimed to be the first minimally intrusive expandable spacer.
ZMH: 119.33 (+1.18), GMED: 24.85 (+0.45), EXAC: 22.33 (-0.28), SYK: 94.51 (+1.14)
Exactech (EXAC) Down to Strong Sell On Dismal Q3 Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 12:30PM CST
Exactech Inc.'s (EXAC) lackluster third-quarter 2014 results (reported on Oct 21), with both earnings and revenues missing expectations, have set a negative earnings estimate revision trend for the company.
ICUI: 88.98 (+0.42), BABY: 36.96 (-0.03), EXAC: 22.33 (-0.28), IDXX: 159.08 (+1.72)
Exactech Offers High Growth And Trades At A Discount To Fair Value
Jonathan Weber - at Seeking Alpha - Wed Nov 12, 12:16PM CST
EXAC: 22.33 (-0.28)
Exactech Launches Octane(R) Elevate Peek Spacer System For Lumbar Interbody Fusion Procedures
Business Wire - Tue Nov 11, 6:56AM CST
Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announces that its spine division has launched Octane(R) Elevate, a Poly Ether Ether Ketone (PEEK) spacer system, at the North American Spine Society Annual Meeting (NASS).
EXAC: 22.33 (-0.28)
Exactech Shares Down 10.1% Since SmarTrend's Sell Call (EXAC)
Comtex SmarTrend(R) - Thu Oct 30, 11:08AM CDT
SmarTrend identified a Downtrend for Exactech (NASDAQ:EXAC) on July 17th, 2014 at $23.77. In approximately 4 months, Exactech has returned 10.14% as of today's recent price of $21.36.
EXAC: 22.33 (-0.28)
Organ and Tissue Transplantation Markets - Global Strategic Business Report 2014-2020
M2 - Thu Oct 30, 5:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zx4hg8/organ_and_tissue) has announced the addition of the "Organ and Tissue Transplantation - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. This report analyzes the worldwide markets for Organ and Tissue Transplantation in Number of Procedures. The global and regional markets (except the US) for 'Organ and Tissue Transplantation' in this report are analyzed by the following Product Segments Organ Tranplantation (Heart, Kidneys, Liver, Pancreas, and Lungs) The US market for 'Organ and Tissue Transplantation' in this report is analyzed by the following Product Segments: - Organ Type (Heart, Kidneys, Liver, Pancreas, Lungs, and Intestine) - Tissue Type (Cornea, Heart Valve, Skin Grafts, Vascular Grafts, Bone Marrow, and Bone Grafts), - Bone Graft Transplantation (By Graft Type: Autologous Graft, Allograft, and Other Materials; By Application Type: General Orthopedics, Spinal Fusions, and Cranio/Maxillofacial). The report profiles 24 companies including many key and niche players such as: - CryoLife, Inc - Exactech, Inc - Folio Biosciences - K?hler Chemie - LifeCell Corporation - Medtronic, Inc. - Organogenesis, Inc. - Organ Recovery Systems - Organ Transport Systems - XVIVO Perfusion AB Key Topics Covered: I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW 2. MARKET TRENDS 3. TECHNOLOGICAL INNOVATIONS 4. MAJOR ISSUES IMPACTING TRANSPLANTATION MARKET 5. PRODUCT OVERVIEW 6. ARTIFICIAL ORGANS - AN ALTERNATIVE TO SOLID ORGAN TRANSPLANTS 7. PRESERVATION SOLUTIONS & IMMUNOSUPPRESSANT DRUGS 8. REGULATORY ENVIRONMENT 9. PRODUCT DEVELOPMENT/INNOVATIONS 10. RECENT INDUSTRY ACTIVITY 11. FOCUS ON SELECT GLOBAL PLAYERS 12. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. EUROPE 4. ASIA-PACIFIC 5. LATIN AMERICA 6. REST OF WORLD IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 24 - The United States (21) - Europe (2) - - Germany (1) - - Rest of Europe (1) - Middle East (1) For more information visit http://www.researchandmarkets.com/research/zx...and_tissue
MDT: 75.26 (+0.33), EXAC: 22.33 (-0.28), CRY: 11.30 (-0.10)
Exactech's (EXAC) CEO David Petty on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Oct 22, 2:57PM CDT
EXAC: 22.33 (-0.28)
Exactech posts 3Q profit
Automated Insights - Tue Oct 21, 3:28PM CDT
GAINSVILLE, Fla. (AP) _ Exactech Inc. (EXAC) on Tuesday reported net income of $3 million, or 21 cents per share, in its third quarter.
EXAC: 22.33 (-0.28)
Exactech Q3 Revenue Up 4% to $57.9 Million; Net Income Down 6% to $3.0 Million Due to Currency Losses; Q3 Diluted EPS $0.21 vs. $0.23
Business Wire - Tue Oct 21, 3:00PM CDT
Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder and spine, announced today revenue of $57.9 million for the third quarter of 2014, a 4% increase over $55.7 million in the third quarter of 2013. Net income was $3.0 million, or $0.21 per diluted share, compared to $3.2 million, or $0.23 per diluted share, in the same quarter a year ago.
EXAC: 22.33 (-0.28)
